Abstract
Autoimmune hemolytic anemia (AIHA) is a well known complication of chronic lymphocytic leukemia (CLL). Steroids are the first line of treatment and there are limited effective treatment options for steroid refractory AIHA of CLL. Rituximab, an active agent against B cell malignancies, has also been noted to be active in certain autoimmune hematologic disorders. We used a combination of rituximab, cyclophosphamide and dexamethasone (RCD) in eight CLL patients with steroid refractory AIHA. Rituximab was given at a dose of 375 mg/m2 i.v. on day 1 (D-1). Cyclophosphamide was given at a dose of 750 mg/m2 on D-2. Twelve mg of dexamethasone was given i.v. on D-1, D-2 and orally from D-3 to D-7. Cycles were repeated every 4 weeks till the best response. Response in AIHA was evaluated by frequent blood counts and Coombs test. All eight patients achieved a remission of their AIHA. Median pretreatment hemoglobin was 8.3 g/dl and post-treatment hemoglobin was 14.3 g/dl. Five patients converted to Coombs negative after RCD. Median duration of response was 13 months (7–23+). Retreatment with RCD was also effective in achieving a response on relapse of AIHA. Our results indicate that a rituximab-based combination regimen (RCD) is highly effective in treating steroid refractory AIHA of CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hamblin TJ, Oscier DJ, Young BJ . Autoimmuntiy in chronic lymphocytic leukemia J Clin Pathol 1986 39: 713–719
Mauro F, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G . Autoimmune hemolytic anemia in chronic lymphocytic leukemia. Clinical, therapeutic and prognostic features Blood 2000 95: 2786–2792
Besa EC . Use of intravenous immunoglobulin in chronic lymphocytic leukemia Am J Med 1987 82: 159–162
Emilia G, Messora C, Bensi L . The use of cyclosporine-A in the treatment of B-chronic lymphocytic leukemia Leukemia 1995 9: 357–359
Caligaris-Cappio F, Hamblin T . B-cell chronic lymphocytic leukemia. A bird of a different feather J Clin Oncol 1999 17: 399–408
Nadler LM, Ritz J, Hardy R, Van Agthoren A, Terhorst C, Schlossman S . A unique cell surface antigen identifying lymphoid malignancies of B-cell origin J Clin Invest 1981 167: 134–140
Anderson KS, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman S, Nadler LM . Expression of human B-cell associated antigen on leukemia and lymphomas: a model of human B-cell differentiation Blood 1994 63: 1424–1433
Reff ME, Carmer K, Chambers KS, Chinn P, Leonard J, Raab R, Newman R, Anderson D . Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD-20 Blood 1994 83: 435–445
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman M, Heyman M, White C, Jain V, Ho A, Wey K, Shen D, Dallaire BK . Rituximab chimeric anti-CD20 antibody therapy for relapsed indolent lymphoma: half of the patients responded to a four-dose treatment program J Clin Oncol 1998 16: 2825–2833
Huhn D, Schiling C, Wilhelm M, Ho A, Hallek M, Knauf W, Riedel U, Srock S, Serke S, Emmerich B for the German CLL Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 2001 98: 1326–1331
Byrd J, Peterson B, Park K, Morrison V, Vardiman J, Jacobson R, Rai KR, Larson R . Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712 Proc Am Acad Oncol 2001 20: 280a
Saleh MN, Gutheil J, Moore M . A pilot study of anti-CD MoAb Rituximab in patients with refractory immune thrombocytopenic purpura (ITP) Blood 2000 95: 252a
Mow BM, Hook CC . Rituximab for the treatment of refractory immune thrombocytopenia: a case report Blood 1999 94 (Suppl. 1): 82b
Perrotta AL, Sunneberg TA, Scott J . Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP) Blood 1999 94: 14a
Lee E, Zamkoff K, Gentile T . Rituxan in the treatment of auto-immune hemolytic anemia (AIHA) Blood 2000 95: 596a
Berentsen S, Tjonnfjord G, Gjertsen B . Rituxan therapy for chronic cold agglutinin disease Blood 2000 95: 730a
Stasi R, Pagano A, Stipa E, Amadori S . Rituximab chimeric anti CD20 monoclonal antibody treatment for adults with idiopathic thrombocytopenic purpura Blood 2001 98: 952–957
Treon S, Anderson K . The use of rituximab in the treatment of mailgnant and non malignant plasma cell disorders Semin Oncol 2000 27: 79–85
Demidem A, Lam T, Alas S, Hariharan K, Hanna A, Bonavida B . chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biother Radiopharm 1997 12: 177–186
Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268–276
Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson L, Keating MJ . Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine Leuk Lymphoma 1993 11: 63–68
Weiss R, Freiman J, Kweder S, Diehl L, Byrd JC . Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia J Clin Oncol 1998 16: 1885–1889
Acknowledgements
This work was made possible by research grant support to Dr Kanti R Rai from The Chemotherapy Foundation, The Edward Brodsky Fund and The Joel Finkelstein Cancer Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gupta, N., Kavuru, S., Patel, D. et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 16, 2092–2095 (2002). https://doi.org/10.1038/sj.leu.2402676
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402676
Keywords
This article is cited by
-
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
Leukemia (2023)
-
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Current Hematologic Malignancy Reports (2017)
-
Current Approaches for the Treatment of Autoimmune Hemolytic Anemia
Archivum Immunologiae et Therapiae Experimentalis (2013)
-
Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia
Leukemia (2011)
-
A 23-year-old woman with 11q-chronic lymphocytic leukemia
Medical Oncology (2011)